Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Merck & Company (MRK – Research Report), with a ...

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Vamil Divan, Guggenheim Securities biopharmaceutical analyst, joins 'Power Lunch' to discuss Merck's troubles in China.

Interestingly, it has been designed by an advertising agency: CHI & Partners, who also look after the energy company’s ad work. The new logo is an updated version ... even doing the work virtually for ...